Recurrent Primary Peritoneal Carcinosarcoma: Clinical Trials

2 trials for Recurrent Primary Peritoneal Carcinosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Active not recruiting 1, Withdrawn 1
Phase 22Active not recruiting 1, Withdrawn 1

Follow Recurrent Primary Peritoneal Carcinosarcoma: new trials by email Literature Review of Recurrent Primary Peritoneal Carcinosarcoma trials Research Report on Recurrent Primary Peritoneal Carcinosarcoma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
Phase 1 / Phase 2WithdrawnNational Cancer Institute (NCI)2025-10-312025-06-03
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma
Phase 1 / Phase 2Active not recruitingMayo Clinic382023-09-282026-09-21

Narrower conditions

Fallopian Tube Neoplasms (1)  ·  Ovarian Neoplasms (1)

Broader conditions

Adnexal Diseases (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Fallopian Tube Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)  ·  Gonadal Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Ovarian Diseases (1)  ·  Urogenital Diseases (1)  ·  Urogenital Neoplasms (1)

Interventions

Magnetic Resonance Spectroscopy (2)  ·  Specimen Handling (2)  ·  ASTX-660 (1)  ·  Bevacizumab (1)  ·  Biopsy (1)  ·  Blood Component Removal (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  Paclitaxel (1)  ·  Taxes (1)  ·  pembrolizumab (1)

Sponsors

Mayo Clinic (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (1)

Top investigators

Kristen P Zeligs (1)  ·  Matthew S. Block, MD, PhD (1)

NIH funding

R01CA276313 (1), U10CA180868 (1)